Aspirin News and Research

RSS
Aspirin also known as acetylsalicylic acid is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet, or "anti-clotting", effect and is used in long-term, low doses to prevent heart attacks, strokes and blood clot formation in people at high risk for developing blood clots. It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.
Changes to flexible spending accounts raise concerns

Changes to flexible spending accounts raise concerns

VIMOVO granted marketing and pricing approval in the UK

VIMOVO granted marketing and pricing approval in the UK

People with anxiety disorders require additional cardiac test: Study

People with anxiety disorders require additional cardiac test: Study

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

PPIs, antiplatelet drugs can help treat CV disease patients at high risk of upper GI bleeding

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

Researchers to determine levels of stroke risk in patients with narrowed brain arteries

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

Using mild painkillers during pregnancy can increase risk of male reproductive disorders

Health reform policy: Flexible spending, device taxes and waivers

Health reform policy: Flexible spending, device taxes and waivers

UC Irvine study: Small amount of brain bleeding is common among older individuals

UC Irvine study: Small amount of brain bleeding is common among older individuals

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

POZEN’s therapeutic development programs qualified to receive federal grant under PPACA

NSAIDs drugs prevent colon cancer: Research

NSAIDs drugs prevent colon cancer: Research

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

POZEN reports net loss of $8.6M for third quarter 2010 vs. net income of $6.7M for third quarter 2009

Consumer groups still concerned as insurance rules are considered by HHS

Consumer groups still concerned as insurance rules are considered by HHS

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Bristol-Myers Squibb 2010 third quarter U.S. net sales increases 4% to $3.1 billion

Aspirin reduces risk of death from prostate cancer

Aspirin reduces risk of death from prostate cancer

Dual antiplatelet therapy study expanded into Australia and New Zealand

Dual antiplatelet therapy study expanded into Australia and New Zealand

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

New Canadian Cardiovascular Society guidelines support clinicians in practicing evidence-based medicine

New guidelines feature various key updates for stroke or TIA survivors

New guidelines feature various key updates for stroke or TIA survivors

CPIC awarded $2.6M grant to examine obesity, cancer risk within California Teachers Study

CPIC awarded $2.6M grant to examine obesity, cancer risk within California Teachers Study

WILD, Sterling Technology announce partnership for Immunel, Tegricel products

WILD, Sterling Technology announce partnership for Immunel, Tegricel products

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.